Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tonix Pharma ( (TNXP) ) has provided an update.
On March 26, 2026, Tonix Pharmaceuticals announced that the first participant was dosed in a Phase 1 investigator-initiated study of TNX-1900, its intranasal potentiated oxytocin candidate. The trial will assess the drug’s effect on trigeminal nerve-mediated vasodilation of the forehead, using a capsaicin and electrical stimulation model of trigeminal neurovascular reactivity in healthy female volunteers.
The study is being led by Professor Antoinette Maassen van den Brink at Erasmus University Medical Center under a collaborative research agreement with Tonix. The initiation of dosing marks an early clinical step in evaluating TNX-1900’s potential role in modulating neurovascular pathways, which could shape the company’s future positioning in neurovascular and headache-related indications if subsequent data are positive.
The most recent analyst rating on (TNXP) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
The score is held back primarily by weak financial performance (large ongoing operating losses and sustained cash burn), despite a relatively low-debt balance sheet. Technicals are mixed with a weak longer-term trend. Offsetting these risks, recent corporate events are notably positive, highlighted by favorable Phase 3 fibromyalgia data and the Nasdaq Global Select uplisting.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company developing product candidates such as TNX-1900, an intranasal potentiated oxytocin formulation. The company focuses on neurological and neurovascular conditions, exploring novel mechanisms and delivery methods to address unmet medical needs in targeted patient populations.
Average Trading Volume: 417,049
Technical Sentiment Signal: Strong Sell
Current Market Cap: $201.1M
See more data about TNXP stock on TipRanks’ Stock Analysis page.